Skip to main content
Erschienen in: Clinical Oral Investigations 3/2010

01.06.2010 | Original Article

MAGE-A antigens in patients with primary oral squamous cell carcinoma

verfasst von: Urs D. A. Müller-Richter, Albert Dowejko, Silvia Peters, Stephan Rauthe, Tobias Reuther, Stefan Gattenlöhner, Torsten E. Reichert, Oliver Driemel, Alexander C. Kübler

Erschienen in: Clinical Oral Investigations | Ausgabe 3/2010

Einloggen, um Zugang zu erhalten

Abstract

MAGE-A antigens are only expressed on tumor cells. The aim of this study was to identify their expression in patients with oral squamous cell carcinoma (OSCC). Forty-seven patients with primary OSCC was selected retrospectively. Histo-pathological sections were stained immunohistochemically with MAGE-A antibody 57B. The results were evaluated regarding tumor size (T), lymph-node metastasis (N), blood vessel infiltration (V), lymph vessel infiltration (L), grading (G), and sex. MAGE-A antigens were expressed in 55% of all patients. Expression increased with tumor size (T1 = 56%; T2 = 44%; T3 = 67%; T4 = 71%). Lymph-node metastasis had no influence (N0 and N1 about 50%). Tumors with blood and lymph vessel infiltration had higher expression (V0 = 50%; V1 = 100%; L0 = 46%; L1 = 71%). Less-differentiated tumors showed higher rates (G1 = 50%; G2 = 45%; G3 = 83%). OSCC in men were positive in 62% and in women in 38%. MAGE-A antigens are frequently expressed in OSCC. Their expression seems to increase with tumor dedifferentiation.
Literatur
1.
Zurück zum Zitat Karim-Kos HE, de Vries E, Soerjomataram I, Lemmens V, Siesling S, Coebergh JW (2008) Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s. Eur J Cancer. Comparison of oral and pharyngeal cancer mortality in five countries: France, Italy, Japan, UK and USA from the WHO Mortality Database (1960-2000)):2008 Karim-Kos HE, de Vries E, Soerjomataram I, Lemmens V, Siesling S, Coebergh JW (2008) Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s. Eur J Cancer. Comparison of oral and pharyngeal cancer mortality in five countries: France, Italy, Japan, UK and USA from the WHO Mortality Database (1960-2000)):2008
2.
Zurück zum Zitat Folz BJ, Silver CE, Rinaldo A, Fagan JJ, Pratt LW, Weir N, Seitz D, Ferlito A (2008) An outline of the history of head and neck oncology. Oral Oncol 44(1):2–9CrossRefPubMed Folz BJ, Silver CE, Rinaldo A, Fagan JJ, Pratt LW, Weir N, Seitz D, Ferlito A (2008) An outline of the history of head and neck oncology. Oral Oncol 44(1):2–9CrossRefPubMed
3.
Zurück zum Zitat Scully C, Bagan JV (2008) Recent advances in Oral Oncology 2007: imaging, treatment and treatment outcomes. Oral Oncol 44(3):211–5CrossRefPubMed Scully C, Bagan JV (2008) Recent advances in Oral Oncology 2007: imaging, treatment and treatment outcomes. Oral Oncol 44(3):211–5CrossRefPubMed
4.
Zurück zum Zitat Scanlan MJ, Gure AO, Jungbluth AA, Old LJ, Chen YT (2002) Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev 188:22–32CrossRefPubMed Scanlan MJ, Gure AO, Jungbluth AA, Old LJ, Chen YT (2002) Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev 188:22–32CrossRefPubMed
5.
Zurück zum Zitat Jungbluth AA, Busam KJ, Kolb D, Iversen K, Coplan K, Chen YT, Spagnoli GC, Old LJ (2000) Expression of MAGE-antigens in normal tissues and cancer. Int J Cancer 85(4):460–5CrossRefPubMed Jungbluth AA, Busam KJ, Kolb D, Iversen K, Coplan K, Chen YT, Spagnoli GC, Old LJ (2000) Expression of MAGE-antigens in normal tissues and cancer. Int J Cancer 85(4):460–5CrossRefPubMed
6.
Zurück zum Zitat Duan Z, Duan Y, Lamendola DE, Yusuf RZ, Naeem R, Penson RT, Seiden MV (2003) Overexpression of MAGE/GAGE genes in paclitaxel/doxorubicin-resistant human cancer cell lines. Clin Cancer Res 9(7):2778–85PubMed Duan Z, Duan Y, Lamendola DE, Yusuf RZ, Naeem R, Penson RT, Seiden MV (2003) Overexpression of MAGE/GAGE genes in paclitaxel/doxorubicin-resistant human cancer cell lines. Clin Cancer Res 9(7):2778–85PubMed
7.
Zurück zum Zitat Kasuga C, Nakahara Y, Ueda S, Hawkins C, Taylor MD, Smith CA, Rutka JT (2008) Expression of MAGE and GAGE genes in medulloblastoma and modulation of resistance to chemotherapy. Laboratory investigation. J Neurosurg Pediatrics 1(4):305–13CrossRef Kasuga C, Nakahara Y, Ueda S, Hawkins C, Taylor MD, Smith CA, Rutka JT (2008) Expression of MAGE and GAGE genes in medulloblastoma and modulation of resistance to chemotherapy. Laboratory investigation. J Neurosurg Pediatrics 1(4):305–13CrossRef
8.
Zurück zum Zitat Suzuki T, Yoshida K, Wada Y, Hamai Y, Sentani K, Oue N, Yasui W (2007) Melanoma-associated antigen-A1 expression predicts resistance to docetaxel and paclitaxel in advanced and recurrent gastric cancer. Oncol Rep 18(2):329–36PubMed Suzuki T, Yoshida K, Wada Y, Hamai Y, Sentani K, Oue N, Yasui W (2007) Melanoma-associated antigen-A1 expression predicts resistance to docetaxel and paclitaxel in advanced and recurrent gastric cancer. Oncol Rep 18(2):329–36PubMed
9.
Zurück zum Zitat Müller-Richter UDA, Dowejko A, Zhou W, Reichert TE, Driemel O (2008) Different expression of MAGE-A-antigens in foetal and adult keratinocyte cell lines. Oral Oncol 44(7):628–33CrossRefPubMed Müller-Richter UDA, Dowejko A, Zhou W, Reichert TE, Driemel O (2008) Different expression of MAGE-A-antigens in foetal and adult keratinocyte cell lines. Oral Oncol 44(7):628–33CrossRefPubMed
10.
Zurück zum Zitat Bolli M, Kocher T, Adamina M, Guller U, Dalquen P, Haas P, Mirlacher M, Gambazzi F, Harder F, Heberer M, Sauter G, Spagnoli GC (2002) Tissue microarray evaluation of melanoma antigen E (MAGE) tumor-associated antigen expression: potential indications for specific immunotherapy and prognostic relevance in squamous cell lung carcinoma. Ann Surg 236(6):785–93CrossRefPubMed Bolli M, Kocher T, Adamina M, Guller U, Dalquen P, Haas P, Mirlacher M, Gambazzi F, Harder F, Heberer M, Sauter G, Spagnoli GC (2002) Tissue microarray evaluation of melanoma antigen E (MAGE) tumor-associated antigen expression: potential indications for specific immunotherapy and prognostic relevance in squamous cell lung carcinoma. Ann Surg 236(6):785–93CrossRefPubMed
11.
Zurück zum Zitat Brasseur F, Rimoldi D, Liénard D, Lethé B, Carrel S, Arienti F, Suter L, Vanwijck R, Bourlond A, Humblet Y et al (1995) Expression of MAGE genes in primary and metastatic cutaneous melanoma. Int J Cancer 63(3):375–80CrossRefPubMed Brasseur F, Rimoldi D, Liénard D, Lethé B, Carrel S, Arienti F, Suter L, Vanwijck R, Bourlond A, Humblet Y et al (1995) Expression of MAGE genes in primary and metastatic cutaneous melanoma. Int J Cancer 63(3):375–80CrossRefPubMed
12.
Zurück zum Zitat Chitale DA, Jungbluth AA, Marshall DS, Leitao MM, Hedvat CV, Kolb D, Spagnoli GC, Iversen K, Soslow RA (2005) Expression of cancer–testis antigens in endometrial carcinomas using a tissue microarray. Mod Path 18(1):119–26CrossRef Chitale DA, Jungbluth AA, Marshall DS, Leitao MM, Hedvat CV, Kolb D, Spagnoli GC, Iversen K, Soslow RA (2005) Expression of cancer–testis antigens in endometrial carcinomas using a tissue microarray. Mod Path 18(1):119–26CrossRef
13.
Zurück zum Zitat Groeper C, Gambazzi F, Zajac P, Bubendorf L, Adamina M, Rosenthal R, Zerkowski HR, Heberer M, Spagnoli GC (2007) Cancer/testis antigen expression and specific cytotoxic T lymphocyte responses in non small cell lung cancer. Int J Cancer 120(2):337–43CrossRefPubMed Groeper C, Gambazzi F, Zajac P, Bubendorf L, Adamina M, Rosenthal R, Zerkowski HR, Heberer M, Spagnoli GC (2007) Cancer/testis antigen expression and specific cytotoxic T lymphocyte responses in non small cell lung cancer. Int J Cancer 120(2):337–43CrossRefPubMed
14.
Zurück zum Zitat Haier J, Owzcareck M, Guller U, Spagnoli GC, Bürger H, Senninger N, Kocher T (2006) Expression of MAGE-A cancer/testis antigens in esophageal squamous cell carcinomas. Anticancer Res. 26(3B):2281–7PubMed Haier J, Owzcareck M, Guller U, Spagnoli GC, Bürger H, Senninger N, Kocher T (2006) Expression of MAGE-A cancer/testis antigens in esophageal squamous cell carcinomas. Anticancer Res. 26(3B):2281–7PubMed
15.
Zurück zum Zitat Sarcevic B, Spagnoli GC, Terracciano L, Schultz-Thater E, Heberer M, Gamulin M, Krajina Z, Oresic T, Separovic R, Juretic A (2003) Expression of cancer/testis tumor associated antigens in cervical squamous cell carcinoma. Oncology 64(4):443–9CrossRefPubMed Sarcevic B, Spagnoli GC, Terracciano L, Schultz-Thater E, Heberer M, Gamulin M, Krajina Z, Oresic T, Separovic R, Juretic A (2003) Expression of cancer/testis tumor associated antigens in cervical squamous cell carcinoma. Oncology 64(4):443–9CrossRefPubMed
16.
Zurück zum Zitat Sharma P, Shen Y, Wen S, Bajorin DF, Reuter VE, Old LJ, Jungbluth AA (2006) Cancer–testis antigens: expression and correlation with survival in human urothelial carcinoma. Clin Cancer Res 12(18):5442–7CrossRefPubMed Sharma P, Shen Y, Wen S, Bajorin DF, Reuter VE, Old LJ, Jungbluth AA (2006) Cancer–testis antigens: expression and correlation with survival in human urothelial carcinoma. Clin Cancer Res 12(18):5442–7CrossRefPubMed
17.
Zurück zum Zitat Rimoldi D, Salvi S, Schultz-Thater E, Spagnoli GC, Cerottini JC (2000) Anti-MAGE-3 antibody 57B and anti-MAGE-1 antibody 6C1 can be used to study different proteins of the MAGE-A family. Int J Cancer 86(5):749–51CrossRefPubMed Rimoldi D, Salvi S, Schultz-Thater E, Spagnoli GC, Cerottini JC (2000) Anti-MAGE-3 antibody 57B and anti-MAGE-1 antibody 6C1 can be used to study different proteins of the MAGE-A family. Int J Cancer 86(5):749–51CrossRefPubMed
18.
Zurück zum Zitat Ries J, Schultze-Mosgau S, Neukam F, Diebel E, Wiltfang J (2005) Investigation of the expression of melanoma antigen-encoding genes (MAGE-A1 to -A6) in oral squamous cell carcinomas to determine potential targets for gene-based cancer immunotherapy. Int J Oncol 26(3):817–24PubMed Ries J, Schultze-Mosgau S, Neukam F, Diebel E, Wiltfang J (2005) Investigation of the expression of melanoma antigen-encoding genes (MAGE-A1 to -A6) in oral squamous cell carcinomas to determine potential targets for gene-based cancer immunotherapy. Int J Oncol 26(3):817–24PubMed
19.
Zurück zum Zitat Ries J, Vairaktaris E, Mollaoglu N, Wiltfang J, Neukam FW, Nkenke E (2008) Expression of melanoma-associated antigens in oral squamous cell carcinoma. J Oral Pathol & Med 37(2):88–93 Ries J, Vairaktaris E, Mollaoglu N, Wiltfang J, Neukam FW, Nkenke E (2008) Expression of melanoma-associated antigens in oral squamous cell carcinoma. J Oral Pathol & Med 37(2):88–93
20.
Zurück zum Zitat Kienstra MA, Neel HB, Strome SE, Roche P (2003) Identification of NY-ESO-1, MAGE-1, and MAGE-3 in head and neck squamous cell carcinoma. Head Neck 25(6):457–63CrossRefPubMed Kienstra MA, Neel HB, Strome SE, Roche P (2003) Identification of NY-ESO-1, MAGE-1, and MAGE-3 in head and neck squamous cell carcinoma. Head Neck 25(6):457–63CrossRefPubMed
21.
Zurück zum Zitat Figueiredo DL, Mamede RC, Proto-Siqueira R, Neder L, Silva WA Jr, Zago MA (2006) Expression of cancer testis antigens in head and neck squamous cell carcinomas. Head Neck 28(7):614–9CrossRefPubMed Figueiredo DL, Mamede RC, Proto-Siqueira R, Neder L, Silva WA Jr, Zago MA (2006) Expression of cancer testis antigens in head and neck squamous cell carcinomas. Head Neck 28(7):614–9CrossRefPubMed
22.
Zurück zum Zitat Lee KD, Lee HH, Joo HB, Lee HS, Yu TH, Chang HK, Jeon CH, Park JW (2006) Expression of MAGE A 1–6 mRNA in sputa of head and neck cancer patients–a preliminary report. Anticancer Res. 26(2B):1513–8PubMed Lee KD, Lee HH, Joo HB, Lee HS, Yu TH, Chang HK, Jeon CH, Park JW (2006) Expression of MAGE A 1–6 mRNA in sputa of head and neck cancer patients–a preliminary report. Anticancer Res. 26(2B):1513–8PubMed
23.
Zurück zum Zitat Vantomme V, Dantinne C, Amrani N, Permanne P, Gheysen D, Bruck C, Stoter G, Britten CM, Keilholz U, Lamers CH, Marchand M, Delire M, Guéguen M (2004) Immunologic analysis of a phase I/II study of vaccination with MAGE-3 protein combined with the AS02B adjuvant in patients with MAGE-3-positive tumors. J Immunother 27(2):124–35CrossRefPubMed Vantomme V, Dantinne C, Amrani N, Permanne P, Gheysen D, Bruck C, Stoter G, Britten CM, Keilholz U, Lamers CH, Marchand M, Delire M, Guéguen M (2004) Immunologic analysis of a phase I/II study of vaccination with MAGE-3 protein combined with the AS02B adjuvant in patients with MAGE-3-positive tumors. J Immunother 27(2):124–35CrossRefPubMed
24.
Zurück zum Zitat Atanackovic D, Altorki NK, Cao Y, Ritter E, Ferrara CA, Ritter G, Hoffman EW, Bokemeyer C, Old LJ, Gnjatic S (2008) Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming. Proc Natl Acad Sci USA 105(5):1650–5CrossRefPubMed Atanackovic D, Altorki NK, Cao Y, Ritter E, Ferrara CA, Ritter G, Hoffman EW, Bokemeyer C, Old LJ, Gnjatic S (2008) Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming. Proc Natl Acad Sci USA 105(5):1650–5CrossRefPubMed
25.
Zurück zum Zitat Atanackovic D, Blum I, Cao Y, Wenzel S, Bartels K, Faltz C, Hossfeld DK, Hegewisch-Becker S, Bokemeyer C, Leuwer R (2006) Expression of cancer-testis antigens as possible targets for antigen-specific immunotherapy in head and neck squamous cell carcinoma. Cancer Biol Ther 5(9):1218–25PubMed Atanackovic D, Blum I, Cao Y, Wenzel S, Bartels K, Faltz C, Hossfeld DK, Hegewisch-Becker S, Bokemeyer C, Leuwer R (2006) Expression of cancer-testis antigens as possible targets for antigen-specific immunotherapy in head and neck squamous cell carcinoma. Cancer Biol Ther 5(9):1218–25PubMed
Metadaten
Titel
MAGE-A antigens in patients with primary oral squamous cell carcinoma
verfasst von
Urs D. A. Müller-Richter
Albert Dowejko
Silvia Peters
Stephan Rauthe
Tobias Reuther
Stefan Gattenlöhner
Torsten E. Reichert
Oliver Driemel
Alexander C. Kübler
Publikationsdatum
01.06.2010
Verlag
Springer-Verlag
Erschienen in
Clinical Oral Investigations / Ausgabe 3/2010
Print ISSN: 1432-6981
Elektronische ISSN: 1436-3771
DOI
https://doi.org/10.1007/s00784-009-0292-2

Weitere Artikel der Ausgabe 3/2010

Clinical Oral Investigations 3/2010 Zur Ausgabe

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Klinikreform soll zehntausende Menschenleben retten

15.05.2024 Klinik aktuell Nachrichten

Gesundheitsminister Lauterbach hat die vom Bundeskabinett beschlossene Klinikreform verteidigt. Kritik an den Plänen kommt vom Marburger Bund. Und in den Ländern wird über den Gang zum Vermittlungsausschuss spekuliert.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Klinik aktuell Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Update Zahnmedizin

Bestellen Sie unseren kostenlosen Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.